Latest Vaccines News

Page 1 of 5
Moderna returned to quarterly GAAP profit, raised its 2026 revenue growth outlook and reported positive Phase 3 melanoma data. The stronger quarter was supported by international COVID vaccine sales, while cash generation and pipeline execution remain important tests.
Ada Torres
Ada Torres
6 Nov 2026
HP has turned to former GSK chief Emma Walmsley to lead the company from January, handing her a compensation package featuring a US$30 million inducement equity award. Interim CEO Bruce Broussard will become chair as the company prepares a significant leadership reset.
Sophie Babbage
Sophie Babbage
5 Nov 2026
Pfizer has lifted its 2026 revenue and adjusted earnings guidance after a quarter in which newer and acquired medicines grew strongly enough to offset steep declines in COVID-19 products. Overall revenue was flat, while reported net income fell 8%.
Victor Sage
Victor Sage
4 Nov 2026
Immutep’s pivotal TACTI-004 lung cancer trial dominates a difficult FY26, with the failure widening the loss to A$79.3 million and triggering an impairment, cost cuts and a root cause review. The biotech retains A$68.9 million in cash, cash equivalents and term deposits, while its remaining investment case rests on IMP761 and selected efti studies.
Ada Torres
Ada Torres
27 Oct 2026
CSL has appointed ViiV Healthcare CEO Deborah Waterhouse to lead the biopharmaceutical group from 1 February 2027. Her arrival comes with a substantial UK-pound-denominated remuneration package and a mandate to renew the pipeline while simplifying operations.
Ada Torres
Ada Torres
21 Oct 2026
AnteoTech has received $1.905 million from the Australian R&D Tax Incentive, providing fresh cash for its battery materials and life sciences commercialisation efforts. The rebate relates to eligible research conducted during the 2026 financial year.
Sophie Babbage
Sophie Babbage
29 Sept 2026
Adheris Health has achieved cashflow break-even in Q4 FY26 following a strategic reset focused on its US operations, cutting costs by over 30% and repositioning for growth in FY27 with a stronger digital pipeline.
Ada Torres
Ada Torres
31 Aug 2026
IDT Australia reports a sharp turnaround in FY26 with a 66% reduction in net loss and an 85% improvement in EBITDA, underpinned by a strategic reset and targeted investments in manufacturing capabilities.
Victor Sage
Victor Sage
20 Aug 2026
CSL Limited’s FY2026 results reveal modest revenue growth offset by a multibillion-dollar statutory loss driven by restructuring and impairments, alongside a maintained dividend and a strategic focus on sustainable growth.
Ada Torres
Ada Torres
18 Aug 2026
Adheris Health’s revenue and profit fell sharply in Q4 FY26 due to the previous challenging pharma budget cycle, but the company achieved cashflow break-even and ended the period with $9.5 million in net cash.
Ada Torres
Ada Torres
23 July 2026
Noxopharm reported significant progress in its Sofra technology, highlighting enhanced cancer drug potential and preparations for a US FDA clinical trial, while managing tight cash reserves.
Ada Torres
Ada Torres
22 July 2026
Green Cross Health Limited reported a 28% rise in net profit to NZD 20.4 million for FY26, driven by gains in both pharmacy and medical divisions. The company announced a conditional sale of its Medical division to Tend Health for NZD 270 million, aiming to refocus on its core pharmacy business.
Ada Torres
Ada Torres
12 June 2026

Browse the archive

Full archive